PharmaResearch Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	603,577	536,289	350,115	261,011	194,759	154,083
Other Revenue	-	-	-	-0	-0	-0
Revenue	603,577	536,289	350,115	261,011	194,759	154,083
Revenue Growth	34.19%	53.17%	34.14%	34.02%	26.40%	41.69%
Cost of Revenue	134,531	125,072	98,878	70,753	53,246	45,750
Gross Profit	469,046	411,217	251,237	190,258	141,513	108,333
Selling, General & Admin	175,886	149,772	94,670	73,828	58,572	42,832
Research & Development	43,559	35,858	21,176	15,030	8,702	6,738
Amortization of Goodwill & Intangibles	4,390	4,294	3,745	3,521	3,796	3,592
Other Operating Expenses	723.44	702.31	618.58	556.23	648.65	313.55
Operating Expenses	233,225	198,891	125,187	98,001	75,597	55,844
Operating Income	235,821	212,327	126,051	92,258	65,916	52,489
Interest Expense	-10,362	-10,392	-4,634	-2,987	-3,830	-1,314
Interest & Investment Income	18,042	16,232	10,174	7,403	5,272	3,726
Earnings From Equity Investments	-5,411	-2,927	-	-	-	-
Currency Exchange Gain (Loss)	11,239	-907.85	4,955	-379.95	207.69	155.77
Other Non Operating Income (Expenses)	-1,806	-1,343	-6,028	3,396	-3,220	124.32
EBT Excluding Unusual Items	247,523	212,989	130,517	99,690	64,346	55,181
Gain (Loss) on Sale of Investments	11,258	5,081	-14,238	4,210	-5,023	1,462
Gain (Loss) on Sale of Assets	39.07	-162.14	-11.92	36.11	-113.69	229.6
Asset Writedown	-2,263	-1,394	-	-3,231	-5,161	-839.66
Other Unusual Items	261.74	-	-454.59	-	-	-
Pretax Income	256,819	216,514	115,813	100,705	54,048	56,033
Income Tax Expense	61,658	48,259	26,870	23,440	10,614	9,210
Earnings From Continuing Operations	195,161	168,255	88,943	77,265	43,434	46,824
Minority Interest in Earnings	-9,471	-3,134	3,100	-713.44	-2,857	-134.98
Net Income	185,690	165,121	92,043	76,551	40,577	46,689
Net Income to Common	185,690	165,121	92,043	76,551	40,577	46,689
Net Income Growth	46.22%	79.40%	20.24%	88.66%	-13.09%	42.45%
Shares Outstanding (Basic)	10	10	10	10	10	10
Shares Outstanding (Diluted)	12	12	10	11	10	10
Shares Change	7.09%	12.34%	-2.50%	5.85%	-0.76%	5.74%
EPS (Basic)	17872.55	15892.83	8940.87	7571.24	4067.47	4716.62
EPS (Diluted)	16711.23	14932.75	8940.87	7487.07	4067.00	4714.88
EPS Growth	39.24%	67.02%	19.42%	84.09%	-13.74%	36.78%

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	137,896	153,435	101,707	52,883	42,147	44,652
Free Cash Flow Per Share	11923.25	13266.86	9879.60	5008.31	4224.85	4441.83
Dividend Per Share	3700.000	3700.000	1100.000	950.000	660.000	600.000
Dividend Growth	236.36%	236.36%	15.79%	43.94%	10.00%	20.00%
Gross Margin	77.71%	76.68%	71.76%	72.89%	72.66%	70.31%
Operating Margin	39.07%	39.59%	36.00%	35.35%	33.84%	34.06%
Profit Margin	30.76%	30.79%	26.29%	29.33%	20.83%	30.30%
Free Cash Flow Margin	22.85%	28.61%	29.05%	20.26%	21.64%	28.98%
EBITDA	252,624	228,142	139,696	104,253	76,518	62,041
EBITDA Margin	41.85%	42.54%	39.90%	39.94%	39.29%	40.27%
D&A For EBITDA	16,803	15,815	13,645	11,996	10,602	9,552
EBIT	235,821	212,327	126,051	92,258	65,916	52,489
EBIT Margin	39.07%	39.59%	36.00%	35.35%	33.84%	34.06%
Effective Tax Rate	24.01%	22.29%	23.20%	23.28%	19.64%	16.44%
Advertising Expenses	-	53,346	29,642	22,601	18,381	9,339